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AbsTrACT
Objective Dysfunction of the blood–nerve barrier 
(BNB) plays important roles in chronic inflammatory 
demyelinating polyneuropathy (cIDp) and multifocal 
motor neuropathy (MMN). The aim of the present study 
was to identify the candidate cytokines/chemokines 
that cause the breakdown of the BNB using sera from 
patients with cIDp and MMN.
Methods We determined the levels of 27 cytokines and 
chemokines in human peripheral nerve microvascular 
endothelial cells (pnMecs) after exposure to sera 
obtained from patients with cIDp variants (typical cIDp 
and multifocal acquired demyelinating sensory and 
motor neuropathy [MaDsaM]), MMN and amyotrophic 
lateral sclerosis (aLs), and healthy controls (hc), using 
a multiplexed fluorescent bead-based immunoassay 
system.
results The induced protein (Ip)10 level in the cells 
in both the MaDsaM and MMN groups was markedly 
increased in comparison with the typical cIDp, aLs and 
hc groups. The other cytokines, including granulocyte 
colony-stimulating factor,vascular endothelial growth 
factor (VeGF) and interleukin-7, were also significantly 
upregulated in the MaDsaM group. The increase of 
Ip-10 produced by pnMecs was correlated with the 
presence of conduction block in both the MaDsaM and 
MMN groups.
Conclusion The autocrine secretion of Ip-10 induced 
by patient sera in pnMecs was markedly upregulated 
in both the MaDsaM and MMN groups. The 
overproduction of Ip-10 by pnMecs leads to the focal 
breakdown of the BNB and may help to mediate the 
transfer of pathogenic T cells across the BNB, thereby 
resulting in the appearance of conduction block in 
electrophysiological studies of patients with MaDsaM 
and MMN.
INTrOduCTION
Chronic inflammatory demyelinating polyneurop-
athy (CIDP) is an immune-mediating neuropathy 
characterised by electrophysiological and patho-
logical evidence of peripheral nerve demyelination. 
The European Federation of Neurological Societies 
and the Peripheral Nerve Society (EFNS ⁄ PNS) clas-
sified CIDP into two clinical subtypes, which show 
different features: typical CIDP (t-CIDP) and atyp-
ical CIDP (eg, multifocal acquired demyelinating 
sensory and motor neuropathy [MADSAM]).1 
Patients with t-CIDP show relatively uniform mani-
festations characterised by symmetric motor-dom-
inant polyneuropathy.2 In contrast, MADSAM 
neuropathy is clinically characterised by multiple 
mononeuropathy, which is involved in multifocal 
nerve conduction block (CB) on nerve conduc-
tion studies.3 4 The difference in these clinical 
phenotypes suggests the possibility of a different 
immunopathogenesis.5
Multifocal motor neuropathy (MMN) is an 
acquired motor neuropathy that is characterised 
electrophysiologically by the presence of multifocal 
persistent CBs on motor nerves but not on sensory 
nerves.6 The disease is considered to have an immu-
nological basis, mostly based on clinical improve-
ment after immune therapy including high-dose 
intravenous immunoglobulin (IVIg) treatment. Basi-
cally, MADSAM can be distinguished from MMN 
by the presence of overt sensory involvement and 
responsiveness to steroid therapy, although MMN 
and MADSAM share a similar electrophysiological 
feature, the presence of CB.6 7
The breakdown of the blood–nerve barrier 
(BNB) is an important step in the pathogenesis of 
CIDP and MMN.8 9 Using our established human 
in vitro BNB model, we previously demonstrated 
that the pattern and severity of the BNB breakdown 
induced by sera differ among t-CIDP, MADSAM 
and MMN.10 11 However, little is known about 
the importance of the BNB breakdown induced by 
cellular immunity in patients with CIDP and MMN. 
In our present study, we compared the levels of 27 
cytokines/chemokines produced by the endothelial 
cells comprising the BNB after exposure to sera 
obtained from patients with t-CIDP, MADSAM and 
MMN, and healthy controls (HCs).
MATerIAls ANd MeThOds
sera
Written informed consent was obtained from each 
participant. As previously described, sera were 
collected from a total of 22 patients with CIDP 
(t-CIDP, n=12; MADSAM, n=10) who met the 
clinical criteria for CIDP based on the 2010 EFNS/
PNS guideline.1 10 Sera were also obtained from 11 
patients with MMN who fulfilled the diagnostic 
criteria for possible MMN based on the guidelines 
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with definite amyotrophic lateral sclerosis (ALS) (diagnosed by 
the El Escorial criteria) were included as disease controls.13 Sera 
from 10 healthy individuals were used as HCs. All serum samples 
were immediately stored at −80°C until the analysis and were 
inactivated at 56°C for 30 min immediately before the analysis.
The clinical data of all patients with CIDP/MMN were anal-
ysed. The clinical course in all patients with CIDP/MMN showed 
a stepwise or continuous worsening without treatment. The 
cerebrospinal fluid (CSF) protein and CSF/serum albumin ratio 
(Q Albumin) were collected from CSF samples from 25 patients 
with CIDP. The total Medical Research Council (MRC) scale 
values in four muscle groups (weaker side of the deltoid, wrist 
extensor, iliopsoas and tibialis anterior muscles) were collected 
for clinical evaluation. All 25 patients with CIDP received corti-
costeroid or IVIg treatment, and all 11 patients with MMN 
received IVIg treatment. Treatment was considered to be effective 
when the MRC score improved after treatment. Nerve conduc-
tion studies were performed using a standard electromyography 
machine (Neuropack M1, Nihon Kohden, Tokyo, Japan; Viking 
4, Nicolet Biomedical Japan, Tokyo, Japan). Motor nerve studies 
of the median, ulnar and tibial nerves, including F wave analyses, 
were performed. A partial motor CB was defined as a >50% 
reduction in the compound muscle action potentials (CMAP) 
between the stimulus sites in accordance with the EFNS/PNS 
guideline.1 10 12
Cell culture and treatment
Immortalised human BNB-comprising endothelial cells, named 
‘FH-BNB cells’, were described previously.14 The cells were 
cultured in a medium containing 10% serum from the patients 
or HCs in a CO2 incubator at 37°C. The total proteins were 
extracted from the cells 1 day after the conditioned media were 
completely removed.
Multiplexed fluorescent bead-based immunoassays
The concentrations of 27 cytokines/chemokines in equal 
amounts of protein (22.5 µg) from each sample obtained from 
cells after exposure to sera were analysed using Bio-Plex Human 
27-Plex Cytokine Panels and a Bio-Plex Cytokine Reagent Kit 
(Bio-Rad, Hercules, California) in accordance with the manufac-
turer’s instructions. The levels of interleukin (IL)-1β, IL-2, IL-4, 
IL-5, IL-6, IL-7, CXCL8/IL-8, IL-9, IL-10, IL-12 (p70), IL-13, 
IL-15, IL-17, IL-1 receptor antagonist (IL-1ra), VEGF, granulo-
cyte colony-stimulating factor (G-CSF), platelet-derived growth 
factor (PDGF)-11, fibroblast growth factor (FGF)-2, granulo-
cyte-macrophage colony-stimulating factor (GM-CSF), tumour 
necrosis factor (TNF)-α, interferon (IFN)-γ, CCL2/macrophage 
chemoattractant protein-1 (MCP-1), CCL3/macrophage inflam-
matory protein (MIP)-1α, CCL4/MIP-1β, and CCL5/regulated 
on activation, CCL11/eotaxin, CXCL10/IFN-inducible protein 
of 10 kDa (IP-10) and normal T cell expressed and secreted 
(RANTES) were measured in this study. The concentrations of 
cytokines/chemokines were calculated by referencing a standard 
curve for each set of molecules derived from the various concen-
trations of the standard assays. The approximate lower limits of 
quantification (assay sensitivity) were as follows: IFN-γ, 6.4 pg/
mL; IL-1β, 0.6 pg/mL; IL-1ra, 5.5 pg/mL; IL-2, 1.6 pg/mL; IL-4, 
0.7 pg/mL; IL-5, 0.6 pg/mL; IL-6, 2.6 pg/mL; IL-7, 1.1 pg/mL; 
IL-8, 1.0 pg/mL; IL-9, 2.5 pg/mL; IL-10, 0.3 pg/mL; IL-12, 3.5 
pg/mL; IL-13, 0.7 pg/mL; IL-15, 2.4 pg/mL; IL-17, 3.3 pg/mL; 
IL-1ra, 5.5 pg/mL; VEGF, 3.1 pg/mL; G-CSF, 1.7 pg/mL; PDGF-
BB, 2.9 pg/mL; FGF-2, 1.9 pg/mL; GM-CSF, 2.2 pg/mL; TNF-α, 
6.0 pg/mL; IFN-γ, 6.4 pg/mL; MCP-1, 1.1 pg/mL; MIP-1α, 1.6 
pg/mL; CCL4/MIP-1β, 2.4 pg/mL; eotaxin, 2.5 pg/mL; IP-10, 
6.1 pg/mL; and RANTES, 1.8 pg/mL (Bio-Rad). The specificity 
of this assay has not been reported; however, it is considered to 
be almost the same as the double-sandwich ELISA.
Immunocytochemistry
FH-BNB cells were cultured in a conditioned medium containing 
10% serum from patients (2 MADSAM, 2 t-CIDP, 2 MMN and 2 
ALS)/healthy volunteers (2 individuals) or 5 U/mL IFN-γ (Thermo 
Fisher Scientific; Waltham, Massachusetts, USA). After 24 hours 
of incubation, cells were fixed with 4% paraformaldehyde, 
washed, then permeabilised with 0.3% Triton X. After blocking 
overnight in 5% goat serum in phosphate buffered saline (PBS), 
primary antibodies (IP-10 from R&D; Minneapolis, Minnesota, 
USA) were added (2 hours, room temperature), then mouse-spe-
cific Alexa Fluor secondary antibodies (1:400). Images were 
captured on an LSM 510 META confocal microscope.
data analysis
Statistical analyses were performed using the Prism V.7 soft-
ware program (GraphPad Software). A one-way analysis of 
variance (ANOVA) between individual groups was performed 
using Bonferroni correction or Kruskal-Wallis test (two sides) 
of 27 cytokine and chemokines. All values are expressed as 
mean±SEM. P values of <0.001 (Bonferroni correction) were 
considered to indicate statistical significance. The unpaired 
Mann-Whitney U (single comparison) or one-way ANOVA 
(multiple comparisons) was used (two sides) for analyses of the 
correlation between clinical/electrophysiological parameters and 
the IP-10. Pearson’s correlation coefficients were also used to 
test associations. Fisher’s exact probability test was used to assess 
differences between groups. Two-sided p values of <0.05 were 
considered to indicate statistical significance.
resulTs
Clinical characteristics
The clinical profiles of patients with t-CIDP, MADSAM and 
MMN are described in table 1. The mean total MRC score in 
the four muscle groups in patients with t-CIDP was significantly 
lower in comparison with patients with MADSAM. When sera 
were collected, none of the CIDP and 1 of 11 patients with 
MMN were receiving IVIg treatment. The mean CSF protein 
concentrations in patients with t-CIDP were higher than those in 
patients with MADSAM and MMN. The mean Q Albumin level 
in the t-CIDP group was higher than that in the MADSAM group. 
A nerve conduction study of the median nerve revealed that the 
patients with t-CIDP had a more prolonged average motor nerve 
distal latency and a greater slowing of the mean motor nerve 
conduction than patients with MADSAM and MMN. CB was 
more frequently observed in patients with MADSAM than in 
patients with t-CIDP or MMN. The CMAPs of the groups did 
not differ to a statistically significant extent.
The overproduction of IP-10 by Fh-bNb cells in the MAdsAM 
and MMN groups
The concentrations of 27 cytokines/chemokines were analysed in 
protein samples obtained from the FH-BNB cells after exposure 
to sera from patients with t-CIDP (t-CIDP group), MADSAM 
(MADSAM group) and MMN (MMN group) and healthy indi-
viduals (HC group). Eight of the 27 cytokine/chemokines (IL-2, 
IL-10, IL-15, IL-17, GM-CSF, MCP-1, MIP-1b and IFN-γ) were 
not detected in this assay. Table 1 shows the profiles of the other 
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(n=9) hC (n=12) P values
Clinical profile
Age (year) 53 (±25) 56 (±12) 42 (±19) 70 (±10) 35 (±6) NS
Male:Female 9:3 8:2 7:4 5:4 6:6 NS
Disease duration† (year) 4.2 (±6.9) 4.4 (±5.5) 4.2 (±5.0) 1.9 (±1.6) NA NS
Total MRC score‡ 15.7 (±2.6) 18.3 (±1.5) ND NA NA <0.05*
Treatment when collecting sera§ 0% (0/12) 0% (0/10) 9% (1/11) NA NA NS
Response to treatment¶ 67% (8/12) 80% (8/10) 82% (9/11) NA NA NS
Response to IVIg 44% (4/9) 88% (7/8) 82% (9/11) NA NA NS
CSF protein (mg/dL) 95.3 (±34.7) 55.8 (±31.4) 37.0 (±18.2) NA NA <0.05*, <0.01**
CSF Q Albumin 0.028 (±0.047) 0.009 (±0.006) ND NA NA <0.01*
Motor conduction study (median nerve)
Distal latency (ms) 9.0 (±5.9) 4.7 (±1.0) 3.8 (±1.0) NA NA <0.05*, <0.01**
CV (m/s) 30.2 (±12.6) 42.3 (±8.3) 51.5 (±13.4) NA NA <0.001**
CMAP (mV) 4.6 (±3.4) 6.1 (±3.5) 4.8 (±3.3) NA NA NS
CB†† 58% (7/12) 100% (10/10) 45% (5/11) NA NA <0.05*, <0.01***
*t-CIDP vs MADSAM, **t-CIDP vs MMN, ***MADSAM vs MMN. Data are expressed as mean (±SD) or % (number).
†Disease duration when collecting the samples.
‡Total MRC score (deltoid + wrist extensor + iliopsoas + tibialis anterior).
§IVIg or steroid treatment when collecting the samples.
¶Response to treatment (IVIg or steroid).
††Conduction blocks (median nerve, ulnar nerve, radial nerve or tibial nerve).
ALS, amyotrophic lateral sclerosis; CB, conduction block; CMAP, compound muscle action potential; CSF, cerebrospinal fluid; CV, conduction velocity; HC, healthy control; IVIg, 
intravenous immunoglobulin; MADSAM, multifocal acquired demyelinating sensory and motor neuropathy; MMN, multifocal motor neuropathy; MRC, Medical Research Council; 
NA, not applicable; ND, not determined; t-CIDP, typical chronic inflammatory demyelinating polyradiculoneuropathy.
cells. A comparison of the levels of 15 cytokines/chemokines 
revealed no statistically significant differences between the 
groups.
The levels of four proteins (IL-7, VEGF, G-CSF and IP-10) 
produced by FH-BNB cells in the MADSAM group were signifi-
cantly increased in comparison with the other groups (table 2). 
The IP-10 protein level in both the MADSAM and MMN groups 
was significantly increased in comparison with that in both the 
t-CIDP and HC groups (table 2). Figure 1 shows that the levels 
of four cytokines/chemokines in MADSAM and/or MMN group 
were significantly increased in comparison with the other groups 
(figure 1A–D). Out of these four cytokines/chemokines, the 
amount of IP-10 produced by FH-BNB cells (range, 96.3–225 
pg/mL) was markedly increased in all of the samples from the 
MADSAM group (figure 1D), and was above the upper levels 
recorded in the HC (51.0 pg/mL), ALS (63.2 pg/mL) and t-CIDP 
(60.3 pg/mL) groups. In contrast, the level of IP-10 produced 
by FH-BNB cells was also significantly increased in the MMN 
group (range, 50–165 pg/mL); however, in a few MMN group 
samples, the levels of this chemokine was below the upper levels 
observed in the HC (51.0 pg/mL), ALS (63.2 pg/mL) and t-CIDP 
(60.3 pg/mL) groups.
Overall, the values of the other three cytokines/chemokines 
in the MADSAM group (IL-7 (range, 10.2–20.7 pg/mL), VEGF 
(range, 111–187 pg/mL) and G-CSF (range, 474–1453 pg/mL)) 
were also significantly increased in comparison with the HC, 
ALS and t-CIDP groups (figure 1A–C); however, the levels of 
these cytokines remained within the normal ranges in most of 
the samples in the MADSAM group.
Immunocytochemical analyses showed that the IP-10 expres-
sion in FH-BNB cells was increased after exposure to sera from 
patients with MADSAM and MMN, in comparison with after 
incubation with sera from patients with t-CIDP and ALS and 
HCs (figure 2).
Correlations between the clinical findings and the IP-10 levels 
in patients with CIdP and MMN
We next examined the correlations between the clinical findings 
and the IP-10 levels in FH-BNBs after exposure to sera from 
patients with CIDP/MMN. A higher IP-10 level in BNB was 
associated with the presence of CB in patients with CIDP or 
MMN (figure 3). The IP-10 level was not significantly associated 
with the disease duration from onset, MRC score, response to 
immunotherapy (including IVIg), the amount of CSF protein, 
the Q Albumin or the distal latency/velocity/CMAP amplitude in 
the median nerve.
dIsCussION
Previous studies have demonstrated the levels of various cyto-
kines/chemokines, including TNF-α, IL-8, IL-17, CXCL-9, 
CCL-3 and IP-10, were increased in the serum/CSF of patients 
with t-CIDP. These studies focused on the key roles of these cyto-
kines/chemokines in the pathogenesis of CIDP.15–19 In contrast, 
there have been few studies on the cytokine/chemokine profiles 
in patients with MMN; these studies have shown that the serum 
levels of IL-1 Ra, IL-2, G-CSF and TNF-α in patients with MMN 
were higher than those in the controls.20–22 However, when 
serum/CSF sample from patients was analysed, it was difficult 
to discern whether these cytokines/chemokines were increased 
as important pathogenic molecules or whether they were merely 
non-specifically upregulated as a byproduct of inflammation. In 
the present study, we therefore analysed the cytokine/chemokine 
profiles produced by FH-BNB cells as a result of the cellular 
response after exposure to sera from patients with t-CIDP, 
MADSAM, MMN and ALS and HCs in order to identify the 
pathogenic cytokines/chemokines responsible for the malfunc-
tion of the BNB. We observed that the higher levels of IL-7, 
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(bonferroni correction)Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd)
IL-7 10.9 (1.2) 10.7 (1.2) 10.0 (1.8) 16.2 (2.9) 13.2 (5.4) <0.001 (MADSAM vs t-CIDP)
VEGF 119 (14) 116 (15) 103 (29) 178 (41) 133 (38) <0.001 (MADSAM vs HC, t-CIDP, 
MMN)
G-CSF 491 (91) 511 (90) 458 (106) 778 (261) 559 (171) <0.001 (MADSAM vs ALS)
IP-10 44.2 (4.6) 51.7 (6.5) 48.7 (5.8) 149 (34) 92.1 (41.1) <0.001 (MADSAM vs HC, ALS, 
t-CIDP, MMN)
<0.001 (MMN vs HC, t-CIDP)
IL-4 0.41 (0.44) 0.99 (0.41) 1.12 (0.53) 0.41 (1.28) 1.27 (1.73) NS
IL-9 3.88 (2.04) 4.7 4 (1.39) 3.17 (1.76) 6.89 (2.80) 5.72 (2.36) NS
IL-12 0 (0) 0.69 (2.09) 2.42 (3.02) 4.39 (3.60) 4.45 (3.93) NS
PDGF-BB 86.4 (20.0) 82.4 (38.5) 133 (43) 150 (71) 168 (108) NS
TNF-α 20.7 (71.8) 87.5 (118) 133 (125) 68.1 (144) 130 (268) NS
IL-1β 0 0 0 0.32 (0.66) 0.29 (0.66) NS
IL-5 0.43 (0.63) 1.07 (0.62) 0.78 (0.70) 1.15 (0.90) 1.05 (1.17) NS
IL-6 0 (0) 0.17 (0.52) 0.83 (1.13) 0.46 (0.75) 0.79 (1.43) NS
IL-8 4.85 (1.24) 6.70 (1.56) 6.43 (2.15) 5.98 (3.20) 7.43 (5.17) NS
IL-13 1.88 (0.21) 2.15 (0.30) 2.15 (0.37) 2.34 (0.48) 2.18 (0.73) NS
IL-1ra 0 (0) 1.89 (5.68) 3.73 (8.87) 12.8 (40.4) 10.7 (20.7) NS
FGF-2 243 (56) 253 (70) 256 (39) 212 (44) 300 (233) NS
Eotaxin 3.65 (1.73) 5.23 (1.87) 3.96 (1.85) 7.06 (4.49) 4.35 (3.33) NS
RANTES 272 (82) 249 (93) 228 (136) 207 (121) 249 (110) NS
MIP-1a 0 (0) 0.06 (0.18) 0.06 (0.14) 0.30 (0.95) 0.22 (0.56) NS
Undetermined cytokines: IL-2, IL-10, IL-15, IL-17, GM-CSF, MCP-1, MIP-1b, IFN-γ.
ALS, amyotrophic lateral sclerosis; FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HC, 
healthy controls; IFN-γ, interferon-γ; IL, interleukin; IL-1ra, IL-1 receptor antagonist; IP-10, inducible protein of 10 kDa; MADSAM, multifocal acquired demyelinating sensory and 
motor neuropathy; MCP-1, macrophage chemoattractant protein-1; MIP, macrophage inflammatory protein; MMN, multifocal motor neuropathy; PDGF, platelet-derived growth 
factor; PnMECS, peripheral nerve microvascular endothelial cells; RANTES, CCL4/MIP-1β andCCL5/regulated on activation, normal T cell expressed and secreted; t-CIDP, typical 
chronic inflammatory demyelinating polyneuropathy; TNF-α, tumour necrosis factor-α; VEGF, vascular endothelial growth factor
with MADSAM were significantly higher than after exposure 
to serum from patients with t-CIDP and ALS and HCs. Among 
these cytokines/chemokines, we identified that the level of IP-10 
produced by the cells was markedly increased after incubation 
with sera from patients with MADSAM and MMN, suggesting 
that IP-10 may contribute to the pathogenesis of MADSAM and 
MMN. Furthermore, we found a significant correlation between 
the IP-10 produced by the cells after exposure to sera and the 
presence of CB in nerve conduction studies in both patients with 
CIDP and MMN.
Some reports revealed that the concentration of IP-10 was 
increased in the CSF samples from patients with t-CIDP.15 17 
CXCR3, a chemokine receptor for IP-10, is known as a specific 
chemokine receptor for type 1 helper T cells (Th1 cells).23–25 
Importantly, in sural nerve biopsy samples from patients with 
t-CIDP, the greatest number of CXCR3-positive T lymphocyte 
in the invading T cells was observed,26 suggesting that endo-
thelial IP-10 can facilitate the trafficking of activated Th1 cells 
expressing the CXCR3 receptor across the BNB.26 Our present 
results suggest that the humoral factors present in the MADSAM 
and MMN sera markedly increase the production of IP-10 
by FH-BNB cells via an autocrine mechanism, and that their 
transfer of CXCR3-positive T lymphocyte to lesion sites across 
the BNB can be mediated.
MADSAM and MMN share a common electrophysiological 
feature: multiple CBs in the peripheral nerve trunk.6 7 The 
focal breakdown of the BNB and the passage of inflamma-
tory cells across the BNB at the site of CB(s) were consid-
ered to be associated with the pathogenesis of MADSAM and 
MMN.5 27 The overproduction of IP-10 by FH-BNB cells may 
induce the migration of T cells across the BNB, and eventually 
lead to the development of inflammatory CB in MADSAM and 
MMN. On the other hand, recent studies have emphasised the 
importance of functional CB in MMN.28–30 The largest series 
of motor nerve biopsies from the site of CB in MMN showed 
multifocal degeneration and a loss of nerve fibre without 
inflammation or lymphocyte infiltration.31 Electrophysiolog-
ical studies of patients with MMN revealed the presence of 
axonal membrane hyperpolarisation due to the overactivation 
of Na+/K+ATPase at the node of Ranvier around the sites of 
CB, resulting in a decrease in the persistent Na+ current.29 30 
The association between inflammatory and functional CBs is 
still elusive; however, we hypothesise that focal inflammation 
and oedema induced by autocrine IP-10 secretion around BNB 
may trigger functional CB in MMN.
IgG4 antibodies against proteins of the paranodal junc-
tion were recently found in 2–10% of patients with CIDP 
who presented the t-CIDP and distal acquired demyelin-
ating symmetric polyneuropathy (DADS) phenotypes, and 
the concept of autoimmune nodoparanodopathy is now 
proposed.32 33 NF155 on the terminal myelin loop and 
contactin 1 on the axonal side are major targets of these anti-
bodies.34 35 Some clinical features, including a poor response 
to IVIg, are different from those in CIDP.35 Myelin loop 
detachment and increased periaxonal space are observed at 
the site of paranode in the sural nerve biopsy, suggesting that 
nerve injury due to the dismantling of the paranode, which 
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Figure 1 The upregulation of cytokines/chemokines in the MaDsaM group. The concentrations of cytokines/chemokines including IL-7 (a), VeGF 
(B), G-csF (c) and Ip-10 (D) in protein samples obtained from Fh-BNB cells after exposure to sera from patients with t-cIDp (t-cIDp group), MaDsaM 
(MaDsaM group), MMN (MMN group) and aLs (aLs group) and healthy volunteers (healthy control group). These four cytokines/chemokines were 
significantly increased in the MaDsaM group compared with the t-cIDp, aLs and healthy control groups (***p<0.001, one-way analysis of variance 
followed by Bonferroni multiple comparison test). Of these four cytokines/chemokines, the Ip-10 levels produced by Fh-BNB cells in the MaDsaM and MMN 
groups were markedly increased in comparison with the aLs and healthy control groups. The dashed lines indicate the upper or lower limits of the cytokine 
levels in the healthy control group (mean±3 sD). healthy control, cells exposed to sera from healthy controls; t-cIDp, cells exposed to sera from patients 
with t-cIDp; MaDsaM, cells exposed to sera from patients with MaDsaM; MMN, cells exposed to sera from patients with MMN; aLs, cells exposed to sera 
from patients with aLs; healthy control, cells exposed to sera from healthy controls. aLs, amyotrophic lateral sclerosis; Fh-BNB cells, immortalized human 
BNB-comprising endothelial cells; G-csF, granulocyte colony-stimulating factor; VeGF, vascular endothelial growth factor; IL-7, interleukin-7; Ip-10, inducible 
protein of 10 kDa; MaDsaM, multifocal acquired demyelinating sensory and motor neuropathy; MMN, multifocal motor neuropathy; t-cIDp, typical chronic 
inflammatory demyelinating polyneuropathy.
mechanism of this disease, rather than segmental demye-
lination and inflammation. In this study, we did not detect 
NF155 antibodies or contactin-1 antibodies in patients with 
CIDP/MMN.36 A further analysis will be needed to clarify the 
pathological mechanism through which these antibodies affect 










6 shimizu F, et al. J Neurol Neurosurg Psychiatry 2018;0:1–7. doi:10.1136/jnnp-2018-319270
Neuromuscular
Figure 2 The increase of Ip-10 in the MaDsaM group using immunohistochemistry. The Ip-10 expression in Fh-BNB cells was assessed by 
immunohistochemistry and was found to be increased after exposure to sera from patients with MaDsaM and MMN, and incubation with IFN-γ, in 
comparison with after exposure to sera from patients with t-cIDp and healthy controls. IFN-γ, cells exposed to 5 U/mL IFN-γ; healthy control, cells exposed 
to sera from healthy controls; t-cIDp, cells exposed to sera from patients with t-cIDp; MaDsaM, cells exposed to sera from patients with MaDsaM; MMN, 
cells exposed to sera from patients with MMN; aLs, cells exposed to sera from patients with aLs. aLs, amyotrophic lateral sclerosis; IFN-γ, interferon-γ; Ip-
10, inducible protein of 10 kDa; MaDsaM, multifocal acquired demyelinating sensory and motor neuropathy; MMN, multifocal motor neuropathy; Fh-BNB 
cells, immortalized human BNB-comprising endothelial cells;  t-cIDp, typical chronic inflammatory demyelinating polyneuropathy; DapI, 4',6-diamidino-2-
phenylindole
Figure 3 The correlation between Ip-10 in Fh-BNB cells after sera exposure and the clinical parameters of patients with cIDp or MMN. a nerve 
conduction study revealed that a higher Ip-10 level was highly associated with the presence of conduction blocks in cIDp (a) and MMN (B). cIDp, cells 
exposed to sera from patients with cIDp, including t-cIDp or MaDsaM; MMN, cells exposed to sera from patients with MMN. statistical significance was 
assessed by the unpaired Mann-Whitney U (*p<0.05). cB, conduction block; cIDp, chronic inflammatory demyelinating polyneuropathy; Fh-BNB cells, 
immortalised human BNB-comprising endothelial cells; Ip-10, inducible protein of 10 kDa; MaDsaM, multifocal acquired demyelinating sensory and motor 
neuropathy; MMN, multifocal motor neuropathy, t-cIDp, typical cIDp.
The serum VEGF levels are elevated in a host of neuropa-
thies, including polyneuropathy, organomegaly, endocrinopathy, 
M-protein and skin change (POEMS) syndrome, CIDP, neuropa-
thies associated with monoclonal gammopathy of undetermined 
significance and Guillain-Barré syndrome.37 The serum VEGF 
concentration is clinically useful for monitoring disease activity 
in POEMS syndrome38; however, the role of serum VEGF in 
other immune-mediated neuropathies is still unclear. VEGF is a 
key regulator of barrier permeability in the blood-brain barrier 
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the BNB in the MADSAM group was significantly increased in 
comparison with the HC, ALS and t-CIDP groups. We previously 
reported the role of VEGF secretion by BNB-endothelial cells 
on the increase in BNB permeability in patients with MMN,11 
although the present study did not show any significant differ-
ences in the VEGF levels of patients with MMN and controls as 
a group. Further retrospective and prospective studies will be 
needed to understand the role of the VEGF and IP-10 produced 
by BNB-endothelial cells as a clinical biomarker of the disease 
activity in CIDP and MMN.
In conclusion, our present study showed that the markedly 
overproduction of IP-10 by the BNB was induced by humoral 
factors in the sera from MADSAM and MMN. Our data suggest 
the potential application of neutralising anti-IP-10 antibodies 
in the treatment of MADSAM and MMN. Further investiga-
tions using the dynamic flow-based in vitro BNB model will be 
required to clarify the association between the IP-10 produced 
by the BNB and the migration of leucocytes, and to better under-
stand the pathogenesis of MADSAM and MMN.
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